Showing 8,041 - 8,060 results of 18,812 for search 'significantly ((((lower decrease) OR (((mean decrease) OR (a decrease))))) OR (greater decrease))', query time: 0.62s Refine Results
  1. 8041

    Table 1_Muscle quality index and hyperuricemia: adipose tissue as a mediator.docx by Ya Shao (16975896)

    Published 2025
    “…Each one-unit increment in MQI corresponded to a 50% decrease in the odds of hyperuricemia (OR: 0.50, 95% CI: 0.43–0.57). …”
  2. 8042

    Inc exhibits key properties of a Cul3 adaptor in neurons in vivo. by Qiuling Li (390393)

    Published 2025
    “…Neuronal <i>Cul3</i> RNAi decreases <i>Cul3</i> transcript levels but does not significantly alter those of <i>inc</i>. …”
  3. 8043

    ELISA kit information. by Shuailin Li (11907158)

    Published 2025
    “…Furthermore, in AN-LSCs, travoprost treatment does not lead to a decrease in NF-κB and ADH7 protein levels.</p></div>…”
  4. 8044

    S1 Data - by Ergang Wang (1459321)

    Published 2024
    “…Meanwhile, plant extract-related treatments significantly increased plant physiological properties and TP (Total protein) content, and decreased the content of MDA (malondialdehyde) by 15.70% -36.59% and PRO (proline) by 30.13% -148.44%. …”
  5. 8045

    Supplementary file 1_Feasibility of repetitive transcranial magnetic stimulation on non-motor symptoms of spinocerebellar ataxia type 3: a secondary analysis of a randomized clinic... by Hua Wu (2707)

    Published 2025
    “…</p>Results<p>The results disclosed significant time effects for all the outcomes with post hoc comparisons showing differences of baseline and post-treatment evaluation, with decreases for PSQI, AIS, HARS, and HDRS as well as increase for MMSE and MoCA. …”
  6. 8046

    Western blot antibody information. by Shuailin Li (11907158)

    Published 2025
    “…Furthermore, in AN-LSCs, travoprost treatment does not lead to a decrease in NF-κB and ADH7 protein levels.</p></div>…”
  7. 8047

    Information on healthy and aniridia subjects. by Shuailin Li (11907158)

    Published 2025
    “…Furthermore, in AN-LSCs, travoprost treatment does not lead to a decrease in NF-κB and ADH7 protein levels.</p></div>…”
  8. 8048

    qPCR primers information. by Shuailin Li (11907158)

    Published 2025
    “…Furthermore, in AN-LSCs, travoprost treatment does not lead to a decrease in NF-κB and ADH7 protein levels.</p></div>…”
  9. 8049

    Image_3_Education and metabolic syndrome: a Mendelian randomization study.pdf by Dong Liu (115204)

    Published 2024
    “…</p>Results<p>Education demonstrated a significant negative correlation with the risk of MetS (OR = 0.55, 95% CI = 0.48–0.63, p = 2.18E−51), waist circumference(OR = 0.80, 95% CI = 0.76–0.83, p = 4.98E-33), hypertension (OR = 0.96, 95% CI = 0.95–0.97; p = 4.54E-10), Fasting blood glucose (OR = 0.94, 95% CI = 0.91–0.97, p = 7.58E-6) and triglycerides (OR = 0.83, 95% CI = 0.79–0.87, p = 7.87E-18) while showing a positive association with high-density lipoprotein cholesterol (OR = 1.22, 95% CI = 1.18–1.25, p = 1.45E-31).…”
  10. 8050

    Image_4_Education and metabolic syndrome: a Mendelian randomization study.pdf by Dong Liu (115204)

    Published 2024
    “…</p>Results<p>Education demonstrated a significant negative correlation with the risk of MetS (OR = 0.55, 95% CI = 0.48–0.63, p = 2.18E−51), waist circumference(OR = 0.80, 95% CI = 0.76–0.83, p = 4.98E-33), hypertension (OR = 0.96, 95% CI = 0.95–0.97; p = 4.54E-10), Fasting blood glucose (OR = 0.94, 95% CI = 0.91–0.97, p = 7.58E-6) and triglycerides (OR = 0.83, 95% CI = 0.79–0.87, p = 7.87E-18) while showing a positive association with high-density lipoprotein cholesterol (OR = 1.22, 95% CI = 1.18–1.25, p = 1.45E-31).…”
  11. 8051

    Image_2_Education and metabolic syndrome: a Mendelian randomization study.pdf by Dong Liu (115204)

    Published 2024
    “…</p>Results<p>Education demonstrated a significant negative correlation with the risk of MetS (OR = 0.55, 95% CI = 0.48–0.63, p = 2.18E−51), waist circumference(OR = 0.80, 95% CI = 0.76–0.83, p = 4.98E-33), hypertension (OR = 0.96, 95% CI = 0.95–0.97; p = 4.54E-10), Fasting blood glucose (OR = 0.94, 95% CI = 0.91–0.97, p = 7.58E-6) and triglycerides (OR = 0.83, 95% CI = 0.79–0.87, p = 7.87E-18) while showing a positive association with high-density lipoprotein cholesterol (OR = 1.22, 95% CI = 1.18–1.25, p = 1.45E-31).…”
  12. 8052

    Image_1_Education and metabolic syndrome: a Mendelian randomization study.pdf by Dong Liu (115204)

    Published 2024
    “…</p>Results<p>Education demonstrated a significant negative correlation with the risk of MetS (OR = 0.55, 95% CI = 0.48–0.63, p = 2.18E−51), waist circumference(OR = 0.80, 95% CI = 0.76–0.83, p = 4.98E-33), hypertension (OR = 0.96, 95% CI = 0.95–0.97; p = 4.54E-10), Fasting blood glucose (OR = 0.94, 95% CI = 0.91–0.97, p = 7.58E-6) and triglycerides (OR = 0.83, 95% CI = 0.79–0.87, p = 7.87E-18) while showing a positive association with high-density lipoprotein cholesterol (OR = 1.22, 95% CI = 1.18–1.25, p = 1.45E-31).…”
  13. 8053

    Description of study characteristics. by Feline de la Court (15194678)

    Published 2025
    “…Loss of PrEP retention rates were significantly (p < 0.05) lower in studies from Europe, Australia and multiple regions (vs. …”
  14. 8054

    Prognostic indicators and survival rates in vulvar cancer: insights from a retrospective study by Tharinee Rahong (21020147)

    Published 2025
    “…Multivariate analysis indicated that coexisting lesions such as Paget’s disease and lichen sclerosus, positive lymphovascular space invasion (LVSI), pelvic or para-aortic lymph node involvement, and positive p53 expression were significantly linked to reduced PFS. Additionally, a tumour size greater than 4 cm was associated with decreased OS. …”
  15. 8055

    Data Sheet 1_A systematic review of the effects of nanoplastics on fish.pdf by Asok K. Dasmahapatra (2275549)

    Published 2025
    “…Among these, NAPs have superior sorption capacity, a large surface area, and a greater ability to release co-contaminants into tissues, resulting in more complex and harmful effects compared to MAPs and MIPs. …”
  16. 8056

    pHI for net status. by Job Oyweri (22041452)

    Published 2025
    “…Against a Bungoma pyrethroid-resistant <i><i>Anopheles gambiae</i></i> s.s<i>,</i> mosquito mortality with pyrethroid-LLINs declined from 36.9% when new to 6.8% at 18 months, while PBO-LLINs dropped from 55.6% to 11.8%.…”
  17. 8057

    Combined net integrity PBO and LLINs-PLOS1. by Job Oyweri (22041452)

    Published 2025
    “…Against a Bungoma pyrethroid-resistant <i><i>Anopheles gambiae</i></i> s.s<i>,</i> mosquito mortality with pyrethroid-LLINs declined from 36.9% when new to 6.8% at 18 months, while PBO-LLINs dropped from 55.6% to 11.8%.…”
  18. 8058

    Factors affecting pyrethroid-LLINs integrity. by Job Oyweri (22041452)

    Published 2025
    “…Against a Bungoma pyrethroid-resistant <i><i>Anopheles gambiae</i></i> s.s<i>,</i> mosquito mortality with pyrethroid-LLINs declined from 36.9% when new to 6.8% at 18 months, while PBO-LLINs dropped from 55.6% to 11.8%.…”
  19. 8059

    Factors associated with mosquito net integrity. by Job Oyweri (22041452)

    Published 2025
    “…Against a Bungoma pyrethroid-resistant <i><i>Anopheles gambiae</i></i> s.s<i>,</i> mosquito mortality with pyrethroid-LLINs declined from 36.9% when new to 6.8% at 18 months, while PBO-LLINs dropped from 55.6% to 11.8%.…”
  20. 8060

    LLINs knockdown performance over time. by Job Oyweri (22041452)

    Published 2025
    “…Against a Bungoma pyrethroid-resistant <i><i>Anopheles gambiae</i></i> s.s<i>,</i> mosquito mortality with pyrethroid-LLINs declined from 36.9% when new to 6.8% at 18 months, while PBO-LLINs dropped from 55.6% to 11.8%.…”